An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
Status:
Completed
Trial end date:
2016-08-11
Target enrollment:
Participant gender:
Summary
This study evaluated the long-term (9-months) safety of the Bimatoprost Ocular Insert in
participants with Glaucoma or Ocular Hypertension who completed study FSV5-004. All the
participants received Bimatoprost Ocular Insert and wore it for approximately 3 months (12
weeks), then had that Insert removed and a new Insert placed for another 26 weeks
(approximately 6 months).